Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Page 1
Gene Therapy: A Possible Alternative to CFTR Modulators?
Mercier J, Ruffin M, Corvol H, Guillot L. Mercier J, et al. Among authors: corvol h. Front Pharmacol. 2021 Apr 21;12:648203. doi: 10.3389/fphar.2021.648203. eCollection 2021. Front Pharmacol. 2021. PMID: 33967785 Free PMC article.
While expected, it is not yet known whether taking these drugs from an early age and for years will improve the quality of life of CF patients in the long term and further increase their life expectancy. Besides, these molecules are not available (specific variants of CFTR …
While expected, it is not yet known whether taking these drugs from an early age and for years will improve the quality of life of CF patien …
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventil

…

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence

…
First Wave of COVID-19 in French Patients with Cystic Fibrosis.
Corvol H, de Miranda S, Lemonnier L, Kemgang A, Reynaud Gaubert M, Chiron R, Dalphin ML, Durieu I, Dubus JC, Houdouin V, Prevotat A, Ramel S, Revillion M, Weiss L, Guillot L, Boelle PY, Burgel PR. Corvol H, et al. J Clin Med. 2020 Nov 10;9(11):3624. doi: 10.3390/jcm9113624. J Clin Med. 2020. PMID: 33182847 Free PMC article.
Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were discharged home without noticeable short-term sequelae. Overall, French CF patients were rarely diagnosed with COVID-19. Further res …
Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were …
Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis.
Perisson C, Destruys L, Grenet D, Bassinet L, Derelle J, Sermet-Gaudelus I, Thumerelle C, Prevotat A, Rosner V, Clement A, Corvol H. Perisson C, et al. Among authors: corvol h. Respir Med. 2017 Dec;133:12-15. doi: 10.1016/j.rmed.2017.11.007. Epub 2017 Nov 10. Respir Med. 2017. PMID: 29173443 Free article.
The mainstay treatment consists of a combination of corticosteroids and antifungals. However, repeated or long-term corticosteroid therapies can lead to serious side effects. The monoclonal anti-IgE antibody, omalizumab, has demonstrated its efficacy in allergic asthma. .. …
The mainstay treatment consists of a combination of corticosteroids and antifungals. However, repeated or long-term corticosteroid th …
Long-term effects of azithromycin in patients with cystic fibrosis.
Samson C, Tamalet A, Thien HV, Taytard J, Perisson C, Nathan N, Clement A, Boelle PY, Corvol H. Samson C, et al. Among authors: corvol h. Respir Med. 2016 Aug;117:1-6. doi: 10.1016/j.rmed.2016.05.025. Epub 2016 May 24. Respir Med. 2016. PMID: 27492507 Free article.
BACKGROUND: Low-dose azithromycin has beneficial effects on severity of the lung disease in cystic fibrosis (CF) patients for a period of 6-12 months after initiation of the treatment. Although its impact in the longer term is uncertain, this treatment is frequently used c …
BACKGROUND: Low-dose azithromycin has beneficial effects on severity of the lung disease in cystic fibrosis (CF) patients for a period of 6- …
Lung sarcoidosis in children: update on disease expression and management.
Nathan N, Marcelo P, Houdouin V, Epaud R, de Blic J, Valeyre D, Houzel A, Busson PF, Corvol H, Deschildre A, Clement A; RespiRare and the French Sarcoidosis groups. Nathan N, et al. Among authors: corvol h. Thorax. 2015 Jun;70(6):537-42. doi: 10.1136/thoraxjnl-2015-206825. Epub 2015 Apr 8. Thorax. 2015. PMID: 25855608
The study is ongoing to provide further information on the very-long-term follow-up of paediatric sarcoidosis....
The study is ongoing to provide further information on the very-long-term follow-up of paediatric sarcoidosis....
[Why use long-term macrolide therapy in pediatric pulmonology?].
Corvol H, Taytard J, Thouvenin G, Périsson C, Nathan N, Clement A. Corvol H, et al. Arch Pediatr. 2014 Mar;21(3):314-21. doi: 10.1016/j.arcped.2013.12.023. Epub 2014 Feb 3. Arch Pediatr. 2014. PMID: 24503457 French.
Since the observation of a dramatic improvement in lung disease and survival in patients with diffuse panbronchiolitis, macrolides have been used over the long term in several chronic respiratory diseases. This review describes the results of trials that have evaluated lon …
Since the observation of a dramatic improvement in lung disease and survival in patients with diffuse panbronchiolitis, macrolides have been …
Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge.
Balloy V, Deveaux A, Lebeaux D, Tabary O, le Rouzic P, Ghigo JM, Busson PF, Boëlle PY, Guez JG, Hahn U, Clement A, Chignard M, Corvol H, Burnet M, Guillot L. Balloy V, et al. Among authors: corvol h. Br J Pharmacol. 2014 Apr;171(7):1783-94. doi: 10.1111/bph.12574. Br J Pharmacol. 2014. PMID: 24417187 Free PMC article.
BACKGROUND AND PURPOSE: Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulating effects. Long-term azithromycin therapy in patients with chronic lung diseases such as cystic fibrosis has been associated with increased antimicrobial resistance, em …
BACKGROUND AND PURPOSE: Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulating effects. Long-term azithro …
13 results